← TrialMatch
HomeTrials

R³ Rehab Pathway Versus Usual Care After Lumbar Radicular Surgery

The R³ trial is a multicentre cluster randomized controlled trial evaluating an evidence-based, person-centred rehabilitation pathway for patients undergoing lumbar surgery for radicular pain. The pathway includes structured pre-, peri-, and postoperative rehabilitation, early postoperative mobilization, case managemen

Condition(s)Lumbar Radiculopathy, Radicular Low Back Pain
StatusRecruiting
PhaseNA
Study typeInterventional
SummaryThe R³ trial is a multicentre cluster randomized controlled trial evaluating an evidence-based, person-centred rehabilitation pathway for patients undergoing lumbar surgery for radicular pain. The pathway includes structured pre-, peri-, and postoperative rehabilitation, early postoperative mobilization, case management, early return-to-work (RTW) guidance, and patient empowerment. Clusters (hospitals) are randomized to implement the R³ pathway (intervention) or continue usual care (control). The primary aim is to determine whether the R³ pathway reduces time to return to work compared with usual care.
Who can participateInclusion Criteria: * Radicular pain (for ≥ 6 weeks prior to screening), with a clear indication for lumbar spinal surgery ((micro)discectomy, decompression and/or fusion), in accordance with the KCE guidelines (when evidence-based multimodal management has not improved pain or function and radiological findings are consistent with clinical symptoms) * Employed (working or on sick leave for less than 1 year due to spinal pathology) * Age 18 - 65 years * Surgery is scheduled within a timeframe of five days to 2 months after the decision for surgery (4 months for fusion) * For lumbar fusion surgery, the fusion should be restricted to one or two levels * Able to provide written informed consent, implying that the participant is both physically and cognitively capable of understanding the stud
Ages18 Years to 65 Years
SexAll
Lead sponsorUniversitaire Ziekenhuizen KU Leuven
LocationsAntwerp, Belgium; Bruges, Belgium; Brussels, Belgium; Charleroi, Belgium; Geel, Belgium; Genk, Belgium (+10 more sites)
Start date2026-03-16
NCT IDNCT07313566
Official listinghttps://clinicaltrials.gov/study/NCT07313566

🔍 Search all trials →